D. E. Shaw & Co., Inc. Reata Pharmaceuticals Inc Call Options Transaction History

D. E. Shaw & Co., Inc.

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $51,220 - $221,920	-2,000 Reduced 16.67%	10,000 $264,000
Q3 2021 Nov 15, 2021	SELL	$100.0 - $143.02 $1.8 Million - $2.57 Million	-18,000 Reduced 60.0%	12,000 $1.21 Million
Q2 2020 Aug 14, 2020	SELL	$126.3 - $176.56 $1.26 Million - $1.77 Million	-10,000 Reduced 25.0%	30,000 $4.68 Million
Q1 2020 May 15, 2020	BUY	$124.16 - $247.74 $3.72 Million - $7.43 Million	30,000 Added 300.0%	40,000 $5.77 Million
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $745,699 - $2.18 Million	10,000 New	10,000 $2.04 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.